Results 91 to 100 of about 1,726,301 (219)

Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes

, 2013
BackgroundThe relationship between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) in type 2 diabetes is currently unknown. We examined the relationship between NAFLD and risk of incident AF in people with type 2 diabetes.Methods ...
Zoppini Giacomo, S. Rodella, Filippo Valbusa, Mantovani William, Mantovani, W., BARBIERI, Enrico, Bertolini Lorenzo, ZOPPINI, Giacomo, L. Zenari, Byrne Christopher D., Zoppini, G., Giacomo Zoppini, Stefano Bonapace, Byrne, Christopher D., Stefano Rodella, Bertolini, L., CD Byrne, Bonapace Stefano, Giovanni Targher, L. Bertolini, Targher, G., Bonapace, S., Valbusa, F., Targher Giovanni, Christopher D Byrne, TARGHER, Giovanni, F. Valbusa, Barbieri, E., MANTOVANI, William, Barbieri Enrico, Rodella, S., Enrico Barbieri, Valbusa Filippo, Luciano Zenari, Zenari, L., William Mantovani, Rodella Stefano, Lorenzo Bertolini, Zenari Luciano, S. Bonapace   +39 more
core   +1 more source

Survival after liver transplantation in the United Kingdom and Ireland compared with the United States

, 2007
<b>Background and Aim</b>: Surgical mortality in the US is widely perceived to be superior to that in the UK. However, previous comparisons of surgical outcome in the two countries have often failed to take sufficient account of case-mix or ...
van der Meulen, JHP, Copley, LP, van der Meulen, J., Gimson, AE, Lewsey, J.D., Dawwas, M.F., Gimson, A.E., Lewsey, JD, Copley, L.P., Dawwas, MF   +9 more
core   +1 more source

Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review

Frontiers in Pharmacology
BackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient.
Yan Wang, Yan Wang, Wenmin Yang, Wenmin Yang, Yuan Yang, Yuan Yang, Xingning Liu, Xingning Liu, Lanfen Peng, Lanfen Peng, Qi Huang, Qi Huang, Qi Huang, Kongli Fan, Kongli Fan, Rui Hu, Rui Hu, Jinyu Yi, Jinyu Yi, Xin Zhong, Xin Zhong, Jing Li, Jialing Sun, Xiaozhou Zhou, Xiaozhou Zhou   +24 more
doaj   +1 more source

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

Virology Journal
Purpose The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB. Methods
Yisi Liu, Shan Ren, Lina Ma, Xiao Lin, Junfeng Lu, Zhenhuan Cao, Sujun Zheng, Zhongjie Hu, Xiaoxue Xu, Xinyue Chen   +9 more
doaj   +1 more source

CyTOF reveals platelet subtype changes predicting the efficacy of combined immunotherapy and targeted therapy in liver cancer

Frontiers in Immunology
IntroductionImmune checkpoint inhibitors combined with angiogenesis inhibitors are currently the first-line treatment for liver cancer. However, some patients still exhibit poor therapeutic outcomes.
Wenjing Wang, Dan Liu, Lilin Wang, Maimaitijiang Wubuli Aishan, Li Chen, Sujun Zheng, Junfeng Lu, Junfeng Lu   +7 more
doaj   +1 more source

Hepatitis B virus-infected hepatocytes promote the secretion of collagen VI to the extracellular matrix

Scientific Reports
Chronic hepatitis B virus (HBV) infection is a global health problem as it is the major cause of liver fibrosis and its complications cirrhosis and hepatocellular carcinoma.
Alessia Virzì, Zakaria Boulahtouf, Julien Moehlin, Lea Girard, Laura Meiss-Heydmann, Charlotte Bach, Emma Gerges, Sarah C. Durand, Marine A. Oudot, Armando A. Roca Suarez, Oliver Popp, Evelyn Ramberger, Philipp Mertins, Emanuele Felli, Patrick Pessaux, Catherine Schuster, Eloi R. Verrier, Thomas F. Baumert, Joachim Lupberger   +18 more
doaj   +1 more source

A time to act: improving liver health and outcomes in liver disease

, 2009
A report prepared by the British Association for the Study of the Liver (BASL) and the British Society of Gastroenterology (BSG) Liver ...
Sheron, Nick
core  

Long-term Management of Alcoholic Liver Disease

, 2012
Alcoholic liver disease is a major cause of morbidity and mortality worldwide. Patients with cirrhosis caused by alcohol are at risk for developing complications associated with a failing liver.
O'Brien, Christopher, Woo, Garmen A
core   +1 more source

Prognostic significance of low hepatic fat content in advanced chronic liver disease: MRI-PDFF insights

Annals of Hepatology
Introduction and Objectives: The mechanisms of hepatic fat loss in late-stage metabolic dysfunction-associated fatty liver disease (MASLD) are enigmatic and the prognostic significance of low hepatic fat content (LHF) in chronic liver disease (CLD) is ...
Atsushi Nakamura, Tsubasa Yoshimura, Takeshi Ichikawa, Keiji Okuyama   +3 more
doaj   +1 more source

Pharmacotherapy for Nonalcoholic Fatty Liver Disease

, 2015
Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease.
Chalasani, Naga, Gawrieh, Samer
core   +1 more source